SANUWAVE Health, Inc. Overview
Pro stress-test →SANUWAVE Health is an emerging leader in developing and commercializing noninvasive, biological response-activating devices for regenerative medicine that repair and regenerate tissue, musculoskeletal, and vascular structures by activating biologic signaling and angiogenic responses. The company's flagship dermaPACE® System is the only focused shockwave therapy cleared by the FDA for treating diabetic foot ulcers, with its key commercialized product being the UltraMIST system, which uses ultrasound technology to treat acute and chronic wounds.
Strategic Profile
Pro stress-test →In Q1 2026, SANUWAVE reported revenue of $9.6 million, up 3.1% year-over-year and the highest Q1 in company history, with 2026 full-year guidance of $51.0–$55.0 million (16–25% growth). The company sold 97 UltraMist systems, with UltraMist consumables revenue rising 15% to $6.7 million, positioning SANUWAVE as a scaled, recurring-revenue wound care platform with FDA-cleared products and a diversified clinical portfolio spanning wound healing, orthopedic, aesthetic, and cardiac applications.
Competitive Landscape
Pro stress-test →SANUWAVE competes in the medical device wound care space, focused on patented regenerative medicine using noninvasive ultrasound or shockwaves to promote tissue repair and regeneration. Key competitors include established wound care providers and regenerative medicine device manufacturers, though SANUWAVE's FDA-cleared dermaPACE® and UltraMIST portfolios provide differentiation in focused shockwave and ultrasound therapy for chronic and diabetic wounds.
Industry Context
SANUWAVE Health, Inc. operates in Advanced wound care and regenerative medicine devices.
Key facts
Founded: 2004 · Headquarters: Eden Prairie, Minnesota, US · Employees: 100+ · Revenue: $9.6M (Q1 2026); guidance $51.0–$55.0M (2026 full-year) · Market cap: N/A